Approval of the Unaudited Standalone Financial Results for third quarter and nine months ended on December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.7 pts less than Nifty Microcap 250 and 7.1 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aspira Pathlab's Board approved its unaudited standalone results for Q3 FY26 (Dec 2025) and nine months ended December 2025. Revenue from operations for Q3 fell sharply to ₹511.88 lakhs from ₹809.28 lakhs in the same quarter last year, a drop of about 37%. The company slipped into a loss before tax of ₹(156.12) lakhs in Q3 versus a profit of ₹183.54 lakhs a year ago, with EPS turning negative at ₹(1.52). For the nine-month period, revenue grew modestly to ₹1,845.96 lakhs (up from ₹1,622.23 lakhs), but profit before tax nearly halved to ₹74.03 lakhs. The auditor (Sarda Soni Associates LLP) issued an unmodified limited review opinion. The Board also approved a material related party transaction with Yashraj Research Foundation for sale of services worth ₹5 crores, subject to shareholder approval.
The steep Q3 revenue decline and swing to a loss are negative signals for near-term investor sentiment, though the nine-month picture still shows topline growth and a small profit. The ₹5 crore related party transaction is subject to shareholder approval, which shareholders should evaluate.